Summary
70 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 44% a year over the last 3 years.
- Out of every 100 GBP of revenue, 46 GBP is left as net profit.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 77% this fiscal year.
What to watch
- It earns only 3.3 GBP a year on every 100 GBP of invested capital.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (REIT - Healthcare Facilities)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 10.2 GBP for 1 GBP of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 19% a year. For the next fiscal year analysts expect revenue to grow by 77%. Earnings per share grew by 44% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, safe- Yield
- 8.12%
- Paid out of profit
- 83%
- Raised in a row
- 3 years
You receive $0.10 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.